Evidence map›Paper›PMID 39886223›Full record

ArticleChemical & biomedical imaging2025

Fluorogenic Tetrazine Bioorthogonal Probes for Advanced Application in Bioimaging and Biomedicine.

Wuyu Mao, Ping Dong, Wei Du, Haoxing Wu

Abstract read
In one paragraph

Article in Chemical & biomedical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wuyu MaoDepartment of Respiratory and Critical Care Medicine, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital of Sichuan University, Chengdu 610041, China.ORCID https://orcid.org/0000-0002-6143-5943
Ping DongDepartment of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Wei DuKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.ORCID https://orcid.org/0000-0003-4162-1471
Haoxing WuDepartment of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging and Functional and Molecular lmaging Key Laboratory of Sichuan Province, West China Hospital of Sichuan University. Chengdu 610041, Sichuan, China.ORCID https://orcid.org/0000-0002-0008-4668

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A variety of bioorthogonal chemical tools have been developed and widely used in the study of biological phenomena in situ. Tetrazine bioorthogonal chemistry exhibits ultrafast reaction kinetics, excellent biocompatibility, and precise optical regulatory capabilities. Fluorogenic tetrazine bioorthogonal probes have achieved particularly diverse applications in bioimaging and disease diagnosis and treatment. This Viewpoint briefly introduces the characteristics and advantages of tetrazine bioorthogonal chemistry, some design strategies of fluorogenic tetrazine probes, and the status of applications of these tools to in vivo imaging, as well as disease diagnosis and treatment. Finally, we discuss challenges and propose future trends in the field of fluorogenic tetrazine probes. This Viewpoint offers insights into the development of new bioorthogonal tools for chemical biology research and for the design of new drugs.

Identifiers

PMID39886223
PMCPMC11775852

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.